$77.03
3.935.38%
At Close: -
$77.05
0.020.03%
After Hours: 6:15 PM EDT
15 minutes delayed
Insmed
INSMNASDAQ
want to know what
the Bulls & Bears Say?
Insmed (NASDAQ:INSM) Stock, Analyst Ratings, Price Targets, Forecasts
Insmed Inc has a consensus price target of $68.68 based on the ratings of 20 analysts. The high is $102 issued by Goldman Sachs on July 10, 2024. The low is $42 issued by Wolfe Research on February 15, 2024. The 3 most-recent analyst ratings were released by Goldman Sachs, Guggenheim, and HC Wainwright & Co. on July 10, 2024, July 9, 2024, and July 8, 2024, respectively. With an average price target of $95.67 between Goldman Sachs, Guggenheim, and HC Wainwright & Co., there's an implied 24.16% upside for Insmed Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Guggenheim
HC Wainwright & Co.
B of A Securities
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Insmed
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 32.38% | Goldman Sachs | Andrea Tan | $74 → $102 | Maintains | Buy | Get Alert |
| 07/09/2024 | Buy Now | 23.3% | Guggenheim | Vamil Divan | $70 → $95 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | 16.81% | HC Wainwright & Co. | Andrew Fein | $70 → $90 | Maintains | Buy | Get Alert |
| 07/05/2024 | Buy Now | 7.72% | B of A Securities | Jason Zemansky | $83 → $83 | Maintains | Buy | Get Alert |
| 07/02/2024 | Buy Now | -9.15% | HC Wainwright & Co. | Andrew Fein | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 07/01/2024 | Buy Now | 14.21% | Truist Securities | Nicole Germino | $68 → $88 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 7.72% | B of A Securities | Jason Zemansky | $62 → $83 | Maintains | Buy | Get Alert |
| 06/21/2024 | Buy Now | -2.66% | Evercore ISI Group | Josh Schimmer | $42 → $75 | Maintains | Outperform | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Jennifer Kim | — | Reiterates | → Overweight | Get Alert |
| 06/20/2024 | Buy Now | -6.55% | JP Morgan | Jessica Fye | $55 → $72 | Maintains | Overweight | Get Alert |
| 06/07/2024 | Buy Now | 6.42% | Mizuho | Graig Suvannavejh | $36 → $82 | Maintains | Buy | Get Alert |
| 06/05/2024 | Buy Now | -3.96% | Stifel | Stephen Willey | $67 → $74 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | -13.04% | Stifel | Stephen Willey | $39 → $67 | Maintains | Buy | Get Alert |
| 05/29/2024 | Buy Now | -13.04% | TD Cowen | Ritu Baral | $45 → $67 | Maintains | Buy | Get Alert |
| 05/29/2024 | Buy Now | -24.72% | UBS | Trung Huynh | $46 → $58 | Maintains | Buy | Get Alert |
| 05/29/2024 | Buy Now | -3.96% | Goldman Sachs | Andrea Tan | $49 → $74 | Maintains | Buy | Get Alert |
| 05/29/2024 | Buy Now | -0.06% | Wells Fargo | Tiago Fauth | $55 → $77 | Maintains | Overweight | Get Alert |
| 05/29/2024 | Buy Now | -11.75% | Truist Securities | Nicole Germino | $48 → $68 | Maintains | Buy | Get Alert |
| 05/29/2024 | Buy Now | -18.23% | Barclays | Leon Wang | $40 → $63 | Maintains | Overweight | Get Alert |
| 05/29/2024 | Buy Now | -28.62% | JP Morgan | Jessica Fye | $36 → $55 | Maintains | Overweight | Get Alert |
| 05/29/2024 | Buy Now | -19.53% | B of A Securities | Jason Zemansky | $40 → $62 | Maintains | Buy | Get Alert |
| 05/29/2024 | Buy Now | -9.15% | HC Wainwright & Co. | Andrew Fein | $52 → $70 | Maintains | Buy | Get Alert |
| 05/28/2024 | Buy Now | -48.09% | B of A Securities | Jason Zemansky | $40 → $40 | Maintains | Buy | Get Alert |
| 05/16/2024 | Buy Now | -37.7% | Truist Securities | Nicole Germino | $48 → $48 | Maintains | Buy | Get Alert |
| 05/15/2024 | Buy Now | -36.4% | Goldman Sachs | Andrea Tan | $40 → $49 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | -32.51% | HC Wainwright & Co. | Andrew Fein | → $52 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | -53.28% | Mizuho | Graig Suvannavejh | $35 → $36 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | -44.19% | Morgan Stanley | Matthew Harrison | $40 → $43 | Maintains | Overweight | Get Alert |
| 04/23/2024 | Buy Now | -37.7% | Truist Securities | Nicole Germino | → $48 | Initiates | → Buy | Get Alert |
| 04/11/2024 | Buy Now | -48.09% | Barclays | Leon Wang | $37 → $40 | Maintains | Overweight | Get Alert |
| 04/01/2024 | Buy Now | -28.62% | Wells Fargo | Tiago Fauth | $55 → $55 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | -29.92% | Guggenheim | Vamil Divan | $52 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | -40.3% | UBS | Trung Huynh | → $46 | Initiates | → Buy | Get Alert |
| 02/15/2024 | Buy Now | -45.49% | Wolfe Research | Andy Chen | → $42 | Initiates | → Outperform | Get Alert |
| 11/20/2023 | Buy Now | -53.28% | JP Morgan | Jessica Fye | → $36 | Reinstates | → Overweight | Get Alert |
| 09/21/2023 | Buy Now | -29.92% | Cantor Fitzgerald | Jennifer Kim | $46 → $54 | Maintains | Overweight | Get Alert |
| 09/19/2023 | Buy Now | -40.3% | Cantor Fitzgerald | Jennifer Kim | → $46 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | Buy Now | -45.49% | Evercore ISI Group | Josh Schimmer | $32 → $42 | Maintains | Outperform | Get Alert |
| 09/06/2023 | Buy Now | -51.98% | B of A Securities | Jason Zemansky | $35 → $37 | Maintains | Buy | Get Alert |
| 09/06/2023 | Buy Now | -32.51% | HC Wainwright & Co. | Andrew Fein | → $52 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | -32.51% | Guggenheim | Vamil Divan | $50 → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | -46.79% | Morgan Stanley | Matthew Harrison | $41 → $41 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | -32.51% | HC Wainwright & Co. | Andrew Fein | → $52 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | Buy Now | -35.11% | Guggenheim | Vamil Divan | → $50 | Initiates | → Buy | Get Alert |
| 05/09/2023 | Buy Now | -32.51% | HC Wainwright & Co. | Andrew Fein | → $52 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | -40.3% | Cantor Fitzgerald | Jennifer Kim | $49 → $46 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | -40.3% | Credit Suisse | Judah Frommer | → $46 | Reiterates | → Outperform | Get Alert |
| 02/24/2023 | Buy Now | -32.51% | HC Wainwright & Co. | Andrew Fein | → $52 | Reiterates | → Buy | Get Alert |
| 01/20/2023 | Buy Now | -54.57% | Barclays | Leon Wang | $37 → $35 | Maintains | Overweight | Get Alert |
| 01/09/2023 | Buy Now | -49.38% | Goldman Sachs | Andrea Tan | $44 → $39 | Maintains | Buy | Get Alert |
| 12/09/2022 | Buy Now | -63.66% | Mizuho | Graig Suvannavejh | → $28 | Initiates | → Buy | Get Alert |
| 12/08/2022 | Buy Now | -51.98% | Barclays | Leon Wang | → $37 | Initiates | → Overweight | Get Alert |
| 12/07/2022 | Buy Now | -51.98% | Barclays | Leon Wang | → $37 | Initiates | → Overweight | Get Alert |
| 11/18/2022 | Buy Now | -49.38% | B of A Securities | Jason Zemansky | → $39 | Initiates | → Buy | Get Alert |
| 10/27/2022 | Buy Now | -35.11% | SVB Leerink | Joseph Schwartz | $52 → $50 | Maintains | Outperform | Get Alert |
| 10/25/2022 | Buy Now | -36.4% | Cantor Fitzgerald | Jennifer Kim | $53 → $49 | Maintains | Overweight | Get Alert |
| 10/21/2022 | Buy Now | -31.21% | Cowen & Co. | Ritu Baral | $56 → $53 | Maintains | Outperform | Get Alert |
| 07/15/2022 | Buy Now | -46.79% | Morgan Stanley | Matthew Harrison | $46 → $41 | Maintains | Overweight | Get Alert |
| 05/24/2022 | Buy Now | -37.7% | Goldman Sachs | Andrea Tan | $56 → $48 | Maintains | Buy | Get Alert |
| 04/27/2022 | Buy Now | -27.32% | Goldman Sachs | Andrea Tan | → $56 | Initiates | → Buy | Get Alert |
| 02/22/2022 | Buy Now | -32.51% | SVB Leerink | Joseph Schwartz | $57 → $52 | Maintains | Outperform | Get Alert |
| 12/06/2021 | Buy Now | -41.6% | JP Morgan | — | — | Initiates | → Overweight | Get Alert |
| 10/08/2021 | Buy Now | -22.13% | Cantor Fitzgerald | Jennifer Kim | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Insmed (INSM) stock?
The latest price target for Insmed (NASDAQ:INSM) was reported by Goldman Sachs on July 10, 2024. The analyst firm set a price target for $102.00 expecting INSM to rise to within 12 months (a possible 32.38% upside). 44 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Insmed (INSM)?
The latest analyst rating for Insmed (NASDAQ:INSM) was provided by Goldman Sachs, and Insmed maintained their buy rating.
When was the last upgrade for Insmed (INSM)?
There is no last upgrade for Insmed
When was the last downgrade for Insmed (INSM)?
There is no last downgrade for Insmed.
When is the next analyst rating going to be posted or updated for Insmed (INSM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insmed was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Insmed (INSM) correct?
While ratings are subjective and will change, the latest Insmed (INSM) rating was a maintained with a price target of $74.00 to $102.00. The current price Insmed (INSM) is trading at is $77.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.